Examining the European Pharma legislation: EFPIA publishes the Dolon Report
- 10 November 2023 - 1 mins read
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation will negatively impact research and development in the pharmaceutical industry in Europe, potentially impacting the lives of patients around the world. Below are some of the projected outcomes if the legislation is adopted.
Find out more about the potential impact: read EFPIA’s press release here and the full report here.
17 October 2024
0 mins read
Financial results for the first nine months of 2024
22 July 2024
0 mins read
Financial results for the first half of 2024
31 May 2024
1 mins read
Our 2023 Integrated Annual Report is live!
19 April 2024
0 mins read
Q1 2024 sales update
15 March 2024
2 mins read
Applications now open for the 2024 Golden Ticket competition
08 February 2024
0 mins read
FY 2023 results announcement
20 November 2023
1 mins read
Ipsen sponsors 5 elite athletes on their journeys to the 2024 Paralympics
03 November 2023
0 mins read
Capital Markets Day 2023
23 October 2023
1 mins read
2023 year to date and third-quarter sales results
20 July 2023
1 mins read